People's Justice is not a law firm and does not provide legal advice.
Attorney advertising. Prior results do not guarantee a similar outcome.
Do You Qualify?
Eligibility Checklist
- Had transvaginal mesh implanted for pelvic organ prolapse (POP) or stress urinary incontinence (SUI)
- Experienced mesh erosion, exposure, or extrusion
- Suffered chronic pelvic pain lasting more than 6 months
- Had dyspareunia (painful intercourse) following implantation
- Required revision or removal surgery to address mesh complications
- Suffered urinary retention, urgency, or recurrent UTIs related to mesh
- Had mesh perforate the bladder, bowel, or blood vessels
- Experienced mesh contraction causing tissue distortion or shortening of the vaginal canal
- Did not previously participate in a global MDL settlement that released all claims
Transvaginal mesh devices are made from polypropylene, a type of plastic with documented biocompatibility concerns when placed in the pelvic cavity long-term. Unlike mesh used in hernia repair (which is largely static), pelvic mesh is subject to constant movement, pressure, and hormonal changes in vaginal tissue. The mesh degrades over time, shrinks, and migrates — causing the characteristic erosion pattern that thousands of women experienced. Manufacturers knew of these risks from European regulatory data and internal studies but continued marketing the devices aggressively, often paying surgeons to train other surgeons in proprietary implantation techniques. Six separate MDLs — covering Ethicon, Bard, Boston Scientific, AMS/Endo, Coloplast, and Neomedic — were consolidated in the Southern District of West Virginia under Judge Goodwin, who was widely considered the country's foremost expert in mesh MDL management. The Ethicon MDL alone (MDL 2327) involved over 48,000 cases.
Transvaginal Mesh Settlement Tier Guide
Settlement values in transvaginal mesh cases depend primarily on injury severity, number of revision surgeries, degree of permanent impairment, and the specific defendant. These ranges reflect outcomes across global MDL settlements, individual state court resolutions, and bellwether trial results.
Mesh Erosion — No Surgery Required
ModerateSettlement Range
Criteria
- Confirmed mesh erosion or exposure on examination
- Chronic pelvic pain or vaginal discomfort lasting 6+ months
- Managed with conservative treatment (topical estrogen, office excision)
- No revision surgery required
- Partial or full resolution of symptoms documented
Mesh Erosion Requiring Partial Removal
SeriousSettlement Range
Criteria
- Mesh erosion requiring surgical intervention
- One partial mesh removal or revision surgery
- Ongoing residual pain or urinary symptoms post-surgery
- Partial recovery with persistent limitations
- Documented impact on sexual function or daily activities
Multiple Revision Surgeries
SevereSettlement Range
Criteria
- Two or more revision or removal surgeries
- Significant chronic pelvic pain despite treatment
- Documented dyspareunia causing relationship and quality-of-life harm
- Bladder or bowel complications requiring additional procedures
- Substantial impact on employment or daily functioning
- Permanent anatomical alteration from mesh contraction
Catastrophic — Organ Damage or Permanent Dysfunction
CatastrophicSettlement Range
Criteria
- Mesh perforation of bladder, bowel, or blood vessels
- Permanent sexual dysfunction (unable to resume intercourse)
- Chronic infection or abscess requiring long-term treatment
- Neuropathic nerve damage causing permanent pain syndrome
- Complete loss of bowel or bladder control
- Multiple major surgeries including colostomy or urostomy
- Documented psychological injury (PTSD, depression) from cumulative harm
These ranges are estimates based on publicly available settlement data and verdict reports. Individual case values depend on specific facts, applicable state law, defendant, and counsel. Past results do not guarantee future outcomes. Consult a qualified attorney for an evaluation of your specific case.
Who Was Harmed: Transvaginal Mesh Patient Exposure Profiles
Common Tasks
- Uses transvaginal mesh products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Common Tasks
- Uses transvaginal mesh products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Common Tasks
- Uses transvaginal mesh products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Common Tasks
- Uses transvaginal mesh products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Internal Documents & Evidence
FDA 2008 Public Health Notification: Serious Complications from Transvaginal Mesh
“”
Impact:
FDA 2011 Safety Communication: Mesh Complications More Serious and Common Than Previously Understood
“”
Impact:
FDA 2019 Market Withdrawal Order: POP Mesh Ordered Off the Market
“”
Impact:
Hrymoc v. Ethicon — $80M Verdict (2019): Largest Transvaginal Mesh Jury Award
“”
Impact:
FDA MAUDE Database: Cumulative Adverse Event Reports 2008–2019 Documenting Scope of Mesh Injury
“”
Impact:
FDA Regulatory Timeline: Transvaginal Mesh Warnings and Market Withdrawal
The FDA issued its first Public Health Notification warning healthcare providers of serious complications associated with transvaginal placement of surgical mesh for POP and SUI repair. The notification catalogued 1,000+ adverse event reports in the MAUDE database covering five years (2000–2007), identifying mesh erosion, infection, pain, urinary problems, and bowel complications as the primary injury categories. Manufacturers were asked to review their labeling and ensure surgeons received adequate training — a voluntary measure that produced no measurable industry response.
The FDA updated its safety communication, now finding that serious complications associated with surgical mesh for transvaginal repair of POP were 'not rare' — a significant escalation from the 2008 language. The FDA had received an additional 2,874 adverse event reports in the three years since 2008, more than doubling the total. The FDA issued 522 post-market surveillance study orders to nine mesh manufacturers, requiring them to conduct prospective clinical studies on their devices. The communication specifically called out the 510(k) clearance pathway as insufficient to establish safety for this device class and stated that it was 'not clear' that transvaginal POP repair with mesh was more effective than traditional non-mesh repair.
The FDA reclassified surgical mesh used for transvaginal repair of pelvic organ prolapse from Class II (moderate risk, 510(k) pathway) to Class III (high risk, requiring Premarket Approval). This was a landmark determination: Class III designation requires manufacturers to submit clinical trial data demonstrating safety and efficacy before marketing — the same standard applied to implantable cardiac devices. The FDA simultaneously ordered manufacturers to submit PMA applications by a specified deadline or cease marketing their POP mesh products. This reclassification effectively acknowledged that the 510(k) pathway had been an error for this device category and that a decade of injuries had occurred because of inadequate premarket review.
The FDA ordered the two remaining manufacturers still selling surgical mesh for transvaginal POP repair — Boston Scientific and Coloplast — to immediately stop selling and distributing their products. The FDA determined that the manufacturers had not provided a reasonable assurance that the probable benefits of these devices outweigh the probable risks. This constituted a mandatory market withdrawal — effectively a recall ordered by the FDA rather than voluntary. The FDA found that the PMA studies submitted failed to demonstrate safety and efficacy and that continued marketing could not be justified. Surgical mesh for SUI (mid-urethral slings) was not included in the withdrawal order and remains on the market under heightened scrutiny.
Johnson & Johnson's Ethicon subsidiary entered a consent decree with the U.S. Department of Justice and FDA resolving allegations related to the marketing and sale of transvaginal mesh products. The consent decree formalized Ethicon's exit from the POP mesh market, required compliance monitoring, and imposed operational restrictions. The decree accompanied Ethicon's $775M+ settlement of civil MDL claims and came after internal J&J documents — obtained in discovery — revealed that Ethicon executives knew of mesh erosion risks as early as the late 1990s but continued aggressive marketing to surgeons without adequate disclosure of complication rates.
Significance Legend
Notable Verdicts & Settlements
Mesh Erosion and Exposure
Medical Definition
Mesh erosion (also called mesh extrusion or exposure) occurs when polypropylene mesh migrates through the vaginal epithelium and becomes exposed in the vaginal canal or adjacent organs. The foreign body reaction to polypropylene causes chronic inflammation, tissue degradation, and progressive erosion. Mesh can also erode into the bladder, bowel, or blood vessels, causing life-threatening complications.
Symptoms
Vaginal discharge or bleeding
CommonPalpable mesh through vaginal wall
CommonPelvic pain and pressure
CommonRecurrent urinary tract infections
CommonPartner discomfort during intercourse
CommonHematuria (blood in urine) if bladder involved
SeriousRisk Factors
- Post-menopausal estrogen deficiency reducing tissue integrity
- Diabetes impairing wound healing
- Prior pelvic surgery causing adhesions
- Smoking reducing tissue perfusion
- Obesity increasing intra-abdominal pressure
- Surgeon inexperience with mesh placement technique
Treatment Options
Chronic Pelvic Pain Syndrome from Mesh
Medical Definition
Chronic pelvic pain (CPP) following transvaginal mesh implantation is a debilitating condition involving persistent pain in the pelvis, lower abdomen, and perineum lasting more than 6 months. The polypropylene mesh causes a chronic foreign body inflammatory response, nerve entrapment within scar tissue, and mechanical tension on pelvic floor musculature. Unlike acute post-surgical pain, CPP from mesh is often permanent and resistant to standard analgesic treatment.
Symptoms
Constant or episodic pelvic pressure and aching
CommonPain radiating to lower back, hips, or inner thighs
CommonWorsening pain with prolonged standing or sitting
CommonPelvic floor muscle spasm
CommonPain with urination or bowel movements
CommonSleep disruption from nocturnal pain
SeriousRisk Factors
- Mesh contraction and shrinkage post-implantation
- Nerve entrapment during trocar passage or mesh anchoring
- Prior pelvic pain conditions
- Surgical technique variations affecting mesh tension
- Duration of implantation — longer implant time increases inflammatory response
Treatment Options
Dyspareunia and Sexual Dysfunction
Medical Definition
Dyspareunia — painful sexual intercourse — is one of the most devastating and underreported complications of transvaginal mesh. The mesh creates rigid scar tissue in the vaginal wall, shortens the vaginal canal through contraction, and causes pain with any penetration. Many women become unable to engage in sexual activity entirely, causing profound impacts on intimate relationships, psychological wellbeing, and quality of life. Male partners often experience discomfort or injury from mesh protrusion.
Symptoms
Severe pain with attempted intercourse
CommonVaginal narrowing or shortening from mesh contraction
CommonPartner discomfort or injury from protruding mesh
SeriousAvoidance of all sexual activity
CommonPsychological distress, depression, relationship damage
SeriousDysorgasmia (painful orgasm)
CommonRisk Factors
- Mesh placement in anterior or posterior vaginal wall
- Excessive mesh tensioning at implantation
- Post-menopausal vaginal atrophy compounding mesh effects
- Multiple overlapping mesh devices
- High mesh density or pore size mismatch
Treatment Options
Mesh Contraction and Vaginal Shortening
Medical Definition
Mesh contraction occurs when the polypropylene implant shrinks over time, pulling surrounding vaginal and pelvic floor tissue with it. Studies have documented mesh shrinkage of 20–50% from its original implanted size. This contraction causes vaginal foreshortening, distortion of pelvic anatomy, nerve entrapment, and worsening prolapse. The contracted mesh creates a rigid, inelastic scar plate that cannot be surgically reversed even if the mesh is partially removed.
Symptoms
Progressive shortening of vaginal canal
SeriousWorsening pelvic pressure and fullness
CommonNew or worsening urinary incontinence
CommonDifficulty with bowel movements (tenesmus)
CommonWorsening dyspareunia as vaginal canal narrows
SeriousVisible or palpable hardening of vaginal wall
CommonRisk Factors
- Type of mesh used (heavyweight, small-pore mesh contracts more)
- Polypropylene degradation producing acidic byproducts
- Chronic infection or hematoma promoting fibrosis
- Patient-specific fibrotic healing response
- Mesh overlap or folding during implantation
Treatment Options
Your Legal Team
Diana Reyes
Senior Partner, Women's Health Litigation
Diana Reyes leads transvaginal mesh litigation across California, where J&J has faced major verdicts exceeding $68 million. Her practice covers both state court cases in Los Angeles County Superior Court and federal cases in California districts. Diana focuses on catastrophic mesh injuries including organ perforation, permanent sexual dysfunction, and the long-term psychological harm caused by mesh complications. She has secured multi-million dollar individual resolutions for California plaintiffs.
Sarah Mitchell
Senior Partner, Mass Torts Division
Sarah Mitchell has litigated transvaginal mesh cases in the Southern District of West Virginia MDL since its formation. As lead coordinating counsel for over 200 individual plaintiffs, she has negotiated MDL bellwether settlements and participated in global mediation sessions with Ethicon, Bard, and Boston Scientific. She focuses exclusively on women's health device litigation.
James Okafor
Senior Trial Attorney
James Okafor represents Texas women injured by transvaginal mesh devices, with a focus on Ethicon TVT and Boston Scientific Advantage cases. He has handled over 150 mesh cases from initial filing through settlement or trial, and served as local counsel in MDL bellwether proceedings in the Southern District of West Virginia. James is particularly experienced in cases involving mesh erosion requiring multiple revision surgeries.
Frequently Asked Questions
Transvaginal Mesh Lawsuit Filing Deadline
In-Depth Guides
C.R. Bard, now part of Becton Dickinson, settled over 3,000 mesh cases for more than $184 million. Its Avaulta, Align, and Ajust mesh products were subjects of MDL 2187, the first major mesh MDL consolidated in West Virginia. Bard's per-case average was approximately $61,333.
Read guideBoston Scientific settled more than 3,000 transvaginal mesh cases for over $188 million, with an average payout of approximately $62,667 — among the highest per-case averages in the mesh litigation. The company's Advantage, Obtryx, Uphold, Pinnacle, and Solyx mesh products are the primary subjects of these claims.
Read guideThere is no single filing deadline — each state has its own statute of limitations, typically 2–3 years. But the discovery rule means the clock starts when you knew or should have known mesh caused your injuries — not when you were implanted. Women implanted a decade ago may still have active claims.
Read guideJohnson & Johnson's Ethicon division paid over $775 million to resolve pelvic mesh claims involving its Gynecare TVT, Prolift, and Prosima devices. Ethicon cases command among the highest individual settlement values in the litigation. SUI mesh cases (TVT/Obtryx) remain active in MDL 2327.
Read guideThe most critical piece of evidence in a mesh lawsuit is the device identification label — a sticker placed in your surgical chart at implantation identifying the manufacturer, device name, and lot number. Combined with records of your complications and treatment, this evidence forms the foundation of your case.
Read guideThe FDA issued its first mesh safety warning in 2008, escalated to an urgent safety communication in 2011 calling complications 'not rare,' and in April 2019 ordered all manufacturers to stop selling transvaginal POP mesh — the most powerful action the FDA can take. This timeline of FDA action is central evidence in every mesh lawsuit.
Read guideMesh used to repair pelvic organ prolapse (POP) transvaginally was ordered off the market by the FDA in April 2019 — the clearest possible regulatory confirmation that these devices were unsafe. Women implanted with POP mesh who experienced erosion, pelvic pain, revision surgery, or sexual dysfunction may qualify for significant compensation.
Read guideYou may qualify for a transvaginal mesh lawsuit if you had mesh implanted for pelvic organ prolapse or stress urinary incontinence and experienced complications including erosion, chronic pain, revision surgery, sexual dysfunction, or organ damage. You do not need to have had a diagnosis of 'mesh erosion' — any documented complication may be sufficient.
Read guideFull transvaginal mesh removal is rarely achievable — the mesh integrates with surrounding tissue, and attempts at complete removal risk damage to the bladder, bowel, and nerves. Most women require multiple partial removal procedures over years, each with its own risks and costs. Every mesh removal surgery is fully compensable as part of a transvaginal mesh lawsuit.
Read guideHaving one or more revision surgeries to address mesh complications significantly increases the value of a transvaginal mesh lawsuit. Each revision surgery represents documented proof of injury severity, additional medical costs, and ongoing harm. The need for revision surgery also often satisfies statute of limitations concerns through the discovery rule.
Read guideGlobal MDL settlements averaged $38,750 to $62,667 per claimant depending on the defendant. Individual cases based on injury severity have settled from $50,000 to over $80 million at verdict. Factors including number of revision surgeries, permanent dysfunction, and defendant significantly affect individual case value.
Read guideTransvaginal mesh complications include erosion through vaginal tissue, chronic pelvic pain, dyspareunia (painful intercourse), mesh contraction, urinary problems, and organ perforation. Many women do not connect their ongoing symptoms to their mesh implant until years later — and may still be eligible to file a lawsuit.
Read guideState-Specific Information
Sources & References
- —
- —
- —